Vismodegib May Benefit Patients with Basal Cell Carcinoma
the Cancer Therapy Advisor take:
Treatment with vismodegib, a Hedgehog pathway inhibitor, may substantially benefit patients with advanced basal cell carcinoma, a recent study published online first in the journal The Lancet Oncology has shown.
For the multicenter, open-label STEVIE trial, researchers sought to evaluate the safety of vismodegib in a situation representative of routine practice, with a long follow-up. Researchers enrolled 1,227 patients with locally advanced or metastatic basal cell carcinoma. Of those, 499 had received vismodegib 150mg orally once daily in 28-day cycles at clinical cutoff.
Results showed that 98% of patients experienced adverse events. The most common adverse events were muscle spasms, alopecia, dysgeusia, diarrhea, nausea, and fatigue. Twenty-one patients died as a result of adverse events.
Researchers found that 66.7% (95% CI: 62.1-71.0) of those with locally advanced disease and 37.9% (95% CI: 20.7-57.7) of those with metastatic disease achieved an overall response.
Vismodegib (Erivedge) was initially approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.
Treatment with vismodegib, a Hedgehog pathway inhibitor, may substantially benefit patients with advanced basal cell carcinoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma
- PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer
- Gemcitabine Plus S-1 May Be Non-inferior to Standard Therapy for Biliary Tract Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances